Who owns ALGS?
Institutional ownership of Aligos Therapeutics Inc. from Form 13F, Q2 2026
31 institutional managers reported holding Aligos Therapeutics Inc. (ALGS) in Form 13F filings for Q2 2026, with 2,292,538 shares worth $13.2M. The largest reported holder was Deep Track Capital, LP. Managers that filed both quarters cut a net 482,548 shares (-17.4%). 5 opened new positions and 8 sold out.
- Funds holding
- 31
- Value held
- $13.2M
- New / sold out
- 5 / 8
- Net shares, same filers
- -17.4%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of ALGS
Share of 13F holdings is each fund's shares as a share of the 2,292,538 ALGS shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- D. E. Shaw & Co., Inc. Added+$320K
- Jane Street Group, LLC New+$187K
- UBS Group AG Added+$132K
- Dimensional Fund Advisors LP New+$121K
- BlackRock, Inc. Added+$100K
- Trexquant Investment LP New+$71K
- Federation des caisses Desjardins du Quebec Added+$21K
- Citigroup Inc New+$10K
- Tower Research Capital LLC (TRC) Added+$2K
- Vanguard Fiduciary Trust Co Added+$1K
Biggest sellers in Q2 2026
- Bank of America Corp Sold out-$1.7M
- SummitTX Capital, L.P. Sold out-$1.1M
- Renaissance Technologies LLC Trimmed-$517K
- Citadel Advisors LLC Sold out-$404K
- LPL Financial LLC Sold out-$383K
- Two Sigma Investments, LP Sold out-$172K
- Marshall Wace, LLP Trimmed-$119K
- XTX Topco Ltd Sold out-$105K
- Quadrature Capital Ltd Sold out-$80K
- Geode Capital Management, LLC Trimmed-$16K
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $967K and sold $4.6M; 7 added and 7 trimmed.
Schedule 13D and 13G filings on ALGS
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-13Parkman Healthcare Partners LLC SCHEDULE 13G filed by Aligos Therapeutics Inc.Schedule 13G
- 2026-06-24BLATT LAWRENCE SCHEDULE 13D filed by Aligos Therapeutics Inc.Schedule 13D
- 2025-08-13Sio Capital Management, LLC SCHEDULE 13G filed by Aligos Therapeutics Inc.Schedule 13G
- 2025-05-15Alyeska Investment Group, L.P. SCHEDULE 13G filed by Aligos Therapeutics Inc.Schedule 13G
- 2025-05-15Woodline Partners LP SCHEDULE 13G filed by Aligos Therapeutics Inc.Schedule 13G
Questions about ALGS ownership
- Who owns ALGS stock?
- 31 institutional investment managers reported ALGS positions in their Form 13F filings for Q2 2026, holding 2,292,538 shares worth $13.2M in total. Deep Track Capital, LP reported the largest position.
- Are funds buying or selling ALGS?
- In Q2 2026, 5 managers opened new ALGS positions, 7 added, 7 trimmed and 8 sold out. Managers that filed in both quarters sold a net 482,548 shares.
- How current is this ALGS institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to ALGS by CUSIP. Options are left out. ALGS news and filings · ALGS insider trades · Top funds